ACHL — Achilles Therapeutics Share News
0.000.00%
Last trade - 00:00Brief: Achilles Therapeutics Presents Positive Data at ESMO I-O Congress 2021 on High-Dose Manufacturing Process for Precision T Cell Therapies Targeting Clonal Neoantigens
Syncona Limited - Achilles Presents Data at the SITC Annual Meeting
Brief: Achilles Therapeutics Reports Data On Cnet And Significant Increase In Cnet Dose From Velos Process 2 Manufacturing
Brief: Secarna Pharmaceuticals And Achilles Therapeutics Sign Research Agreement To Develop Optimized T Cell Therapies
U.S. RESEARCH ROUNDUP-Agiliti, First Western Financial, Shoals Technologies Group
Brief: Achilles Therapeutics Reports Third Quarter 2021 Financial Results And Recent Business Highlights
Brief: Achilles Therapeutics Presents Data At The 2021 European Society For Gene And Cell Therapy (Esgct) Congress
Achilles Therapeutics jumps on U.S., European patents for cancer detection method
Brief: Achilles Therapeutics Announces Grant Of US And European Patents
NASDAQ RESUMED AT 09:56 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:50 AM
Brief: Achilles Therapeutics Posts Q2 Loss Per Share $0.45
Brief: Achilles Therapeutics Enrolls First U.S. Patient In Ongoing Phase I/IIa Study In Advanced Non-Small Cell Lung Cancer
Brief: Achilles Therapeutics Details Phase I/Iia Clinical Trial Design Of Chiron In Patients With Advanced Non-Small Cell Lung Cancer At The 2021 American Society Of Clinical Oncology (Asco) Annual Meeting
Brief: Achilles Therapeutics Reports Q1 Loss Per Share Of $8.38
NASDAQ TRADE HALT REASON NOT AVAILABLE AT 03:58 AM
Brief: Achilles Therapeutics Announces Pricing Of Initial Public Offering
Brief: Achilles Therapeutics PLC Sees U.S. IPO Of 9.75 Million American Depositary Shares Priced Between $17.00 And $19.00 Per ADS - SEC Filing